NCT03564340 2025-12-03Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRegeneron PharmaceuticalsPhase 1/2 Recruiting890 enrolled
NCT04590326 2025-11-21A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRegeneron PharmaceuticalsPhase 1/2 Recruiting612 enrolled
NCT04954599 2025-10-07Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIMaastricht University Medical CenterPhase 1/2 Recruiting126 enrolled
NCT05259696 2025-08-20GLIMMER-01Palleon Pharmaceuticals, Inc.Phase 1/2 Completed69 enrolled 13 charts
NCT05864144 2025-08-15A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSensei Biotherapeutics, Inc.Phase 1/2 Active not recruiting98 enrolled